Delcath Systems (NSDQ:DCTH) filed a new FDA application for the latest iteration of its ChemoSat drug-device combination, the Generation 2 device, in treatment of patients with non-operable liver cancer.
New FDA rules imperil Bioject | Wall Street Beat
Delcath jumps 12% on Euro sales news
Delcath Systems (NSDQ:DCTH) won a lot of Wall Street love today on news that it landed the 1st commercial order for its organ-targeting chemotherapy system, the ChemoSat device.
Carticept closes $10M round from SonoSite, others | Funding Roundup
Carticept Medical closed a $10 million financing led by existing investors Domain Associates, New Enterprise Associates and SonoSite Inc.
The Alpharetta, Ga.-based company said it will use the proceeds to fund the commercial launch of its Navigator computer-controlled drug delivery system. The device uses ultrasound guidance to deliver medications for joint pain.
Stealth drugs: The necessity of drug distribution permits for devices
MassDevice.com +3 | Baxter's CEO reaps $14M, Sapien trial cut short on adverse events, Devices plus drugs pose great potential
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Devices plus drugs may mean an earlier payoff
Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.
Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.
Delcath's ChemoSat goes another round with the FDA
Delcath Systems Inc.’s (NSDQ:DCTH) ChemoSat organ-targeting chemotherapy system will get a pre-new drug application meeting with the FDA mid-January 2012, the company announced this week.
The ChemoSat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ — in this case, the liver — from the rest of the body’s bloodstream.
Will Baxter renew Medgenics drug pump deal?
The top 10 med-tech innovations of 2012 | MassDevice.com On Call
MASSDEVICE ON CALL — The top ten med-tech innovations of 2012, selected by Cleveland Clinic and announced this week spanned the range of health care from detection to treatment to data management.
In the top spot was a system of renal denervation for treatment of high blood pressure. The procedure uses a catheter probe threaded into the renal artery near the kidneys to delivery low-power radio-frequency energy and disrupt nerves, lowering blood pressure.